Prognostic Value of Estimated Plasma Volume in Pulmonary Hypertension

NCT05861479 | Completed

• 1 other identifier: 2022PI167
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Assessment of the prognostic value of the estimation of plasma volume or its variation in patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) after acute right heart failure.

Conditions

Pulmonary Arterial Hypertension; Chronic Thromboembolic Pulmonary Hypertension; Acute Right Heart Failure

Outcome Measures

Primary Outcomes (3)

• Survival

  Death

  From the first visit to 1st April 2023

• Recurrence of acute right heart failure

  Hospital admission for acute right heart failure

  From the first visit to 1st April 2023

• Acute right heart failure-free survival

  First event: death or hospital admission for acute right heart failure

  From the first visit to 1st April 2023

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

One hundred patients with idiopathic, heritable, drug-induced, connective tissue disease-associated, porto-pulmonary or HIV-associated disease were enrolled. At the diagnosis visit, mean±SD age was 59±12 years, 56% of the patients were women and most patients were in World Health Organization/New York Heart Association (WHO/NYHA) Functional Class III or IV.

You may qualify if:

• Patients with confirmed diagnosis of PAH or CTEPH, referred to the medical department of the investigators
• Patient with acute right heart failure defined by at least 2 of the following clinical features: worsening of peripheral oedema, development or increase of ascites, weight gain of more than 2.5 kg in 1 week preceding the visit and decline in one NYHA functional class compared to the previous stable state

You may not qualify if:

• \) Patients with another cause of pulmonary hypertension than PAH or CTEPH, either groups 2, 3 or 5 of the current clinical classification of pulmonary hypertension

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

MeSH Terms

Conditions

Pulmonary Arterial Hypertension

Condition Hierarchy (Ancestors)

Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 5, 2023
• First Posted: May 17, 2023
• Study Start: January 1, 2015
• Primary Completion: January 1, 2023
• Study Completion: April 1, 2023
• Last Updated: May 17, 2023

Record last verified: 2023-04